Financial
FY2025 revenue $10.06bn (+20.5%); operating margin 29.3%; net income $2.86bn.
No debt; $9.03bn cash and investments.
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue $10.06bn (+20.5%); operating margin 29.3%; net income $2.86bn.
No debt; $9.03bn cash and investments.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$10.1bn | +20.5% | US$2.9bn | US$2.9bn | Intuitive Surgical |
Products not yet catalogued.
FY2025 revenue $10.06bn (+20.5%); operating margin 29.3%; net income $2.86bn.
No debt; $9.03bn cash and investments.
Aug 2026: The US Ninth Circuit revived an antitrust claim by Surgical Instrument Service Co. alleging Intuitive unlawfully controlled the aftermarket for da Vinci instruments, reversing a lower court ruling; the claims remain unproven.
Mar 2026: Intuitive disclosed a targeted phishing attack that exposed customer contact, employee and corporate data from internal business applications; it said da Vinci, Ion and digital platforms were not affected and the incident was contained. NHS DSPT status not yet checked.
Dec 2025: Intuitive began a Class 2 recall of da Vinci S/Si Permanent Cautery Hook instruments after more complaints of frayed or broken pitch cables; FDA attributed the cause to process change control.
No notable contract disputes, terminations or significant NHS/UK public sector contracts involving Intuitive Surgical found in HSH's search of the last 24 months.
No competitors linked yet.